Designing robust clinical trials to evaluate antioxidant therapies in HTN and DM requires addressing unique challenges, including patient heterogeneity, biomarker variability, and the dual role of OS as both cause and consequence of disease progression
This has been demonstrated in the SURMOUNT trials, where tirzepatide produced substantial body weight loss and improvements in cardiometabolic risk markers
We believe that a comprehensive, medically supervised approach is the key to lasting success
- Ch n ung v li sng lnh mnh: duy tr ch dinh dng cn i, ung nhiu nc, hn ch thc phm c hi, v rn luyn thi quen tt nh tp th dc, ng gic h tr c th t bn trong
You are currently undergoing chemotherapy or radiation therapy (antioxidants can sometimes interfere with these treatments)